Walleye Trading
CASC

Walleye Trading’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Walleye Trading’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8
Closed – – 5488
2016
Q3 		$0 Hold
8
– – ﹤0.01% 5805
2016
Q2 		$0 Sell
8
-34
-81% -$231 ﹤0.01% 6002
2016
Q1 		$0 Buy
+42
New +$323 ﹤0.01% 6136
2015
Q3 		– Sell
-517
Closed -$12K – 5812
2015
Q2 		$12K Buy
+517
New +$8.18K ﹤0.01% 4243

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Walleye Trading's CASC Position: Q4 2016 in Review

Walleye Trading sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 8 shares.

Walleye Trading first reported a position in CASC in Q2 2015 and held it in 4 quarters. The position peaked at $12K in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • Walleye Trading reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Walleye Trading sold 8 Cascadian Therapeutics, Inc. shares in Q4 2016.
  • Walleye Trading first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 4 quarters.
  • Walleye Trading's Cascadian Therapeutics, Inc. position peaked at $12K in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on Walleye Trading's 13F filing for Q4 2016, filed 14 Feb 2017.